A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
← catalyst calendarNCT05440708 · readout in 166 d
Sponsored by Tvardi Therapeutics, Incorporated (industry) · TVRD — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
193estimated
Sites
21
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-23 | actual | When the study began enrolling |
| Primary completion | 2027-02-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-10 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Interventions
- Drug: TTI-101
- Drug: Pembrolizumab — also filed as Keytruda®
- Drug: Atezolizumab — also filed as Tecentriq®
- Drug: Bevacizumab — also filed as Avastin®
Primary outcomes
what the primary-completion date above is the date OFIncidence of Adverse Events (AE)
measured Up to approximately 20 months
Incidence of Serious Adverse Events (SAE)
measured Up to approximately 18 months
Phase 2: Overall Response Rate (ORR) to TTI-101
measured Up to approximately 18 months
Permalink · TVRD's whole pipeline · Catalyst calendar · Every registered study · What changed